The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...
The global sleep apnea devices market is set to expand at a steady CAGR of 9.5%, growing from USD 8.2 billion in 2023 to USD ...
According to statistics by the American Association of Medicine, the disorder sleep apnea affects approximately 30 million US ...
For patients with obstructive sleep apnea (OSA), sleep surgery is associated with a significantly reduced risk for mo ...